Congrats Mission BioCapital for closing your latest round of funding! We are inspired by your continued commitment to supporting early-stage life science companies with impactful science and technologies. #venturecapital #lifesciences #bayarea #biotech

#RareDiseaseDay is today. We are dedicated to developing meaningful new #PMM2CDG therapies and improving the quality of life for #raredisease patients, families, and caregivers. Learn more here: glycomine.com/glm101/ #PMM2CDG #glycosylation #CDGawareness #rarediseases

Today is #WorldCDGDay, and we are raising awareness for #CDGresearch. We #StandUnited4CDG and are committed to developing new #PMM2CDG therapies to improve the quality of life for people with this #raredisease. Learn more: glycomine.com/pmm2-cdg/ #CDGawareness #rarediseases

We are excited to welcome Steven Axon as CEO and Jacqueline Grant and Jason Hafler to our BOD. Their appointments come at a pivotal stage as we advance GLM101, a potential disease-modifying treatment for #PMM2CDG, in clinical trials. glycomine.com/glycomine-appo…

Today we announce the first patient dosed in a phase 2 #clinicaltrial of GLM101, our lead drug candidate. We look forward to advancing the development of the first potential disease-modifying therapy to be evaluated in #PMM2CDG. glycomine.com/glycomine-anno… #raredisease

Today we welcome Dr. Rose Marino as our CMO, bringing 20+ years of combined experience in pediatric endocrinology and clinical research. She joins us as we advance in #clinicaltrials GLM101, a potential disease-modifying treatment for #PMM2CDG. glycomine.com/glycomine-appo…

We are excited to have presented data at #ASHG23 from our ongoing natural history study, providing insights into genetic mutations and biomarkers for #PMM2CDG. The data will help design future #clinicaltrials for GLM101. glycomine.com/glycomine-pres… #CDGresearch #raredisease

We are excited to announce that the first pediatric patient has been dosed in a Phase 2 clinical study of GLM101, which is in development as the first potential disease-modifying treatment for #PMM2CDG. glycomine.com/glycomine-anno… #CDGresearch #raredisease #clinicaltrials

We’re excited to have presented data at the #RareDiseaseDay2024 Symposium, CDG Scientific and Family Conference showing encouraging efficacy from our ongoing #clinicaltrial of GLM101 in #PMM2CDG. Read the release for more: glycomine.com/glycomine-anno… #CDGresearch #RareDiseaseDay

We are proud to share two new research publications on GLM101, which is in development as the first potential disease-modifying treatment for #PMM2CDG. Click here for free access thru 9/12: authors.elsevier.com/a/1jUGy3vNNNmz… Open access: doi.org/10.1016/j.ymgm… #CDGresearch #rarediseases

Glycomine is pleased to share that we have received FDA Fast Track Designation for GLM101, a potential treatment in #clinicaltrials for #PMM2CDG, a rare genetic disorder of glycosylation. Read the release for more: glycomine.com/glycomine-rece… #CDGresearch #RareDisease #FastTrack

We’re excited to announce that Joshua Grass has been appointed Chairperson of our Board of Directors. We welcome Josh at this pivotal point in our company’s growth as we advance GLM101 in #clinicaltrials for #PMM2CDG. glycomine.com/glycomine-appo… #RareDiseases

We are excited to announce a $115 million Series C to advance GLM101, the first disease-modifying therapy in development for #PMM2CDG, into a Phase 2b clinical trial. Thank you to our new & existing investors for believing in our mission! glycomine.com/glycomine-anno… #CDGresearch

Honored to have our Series C milestone celebrated by NYSE 🏛 as we advance GLM101, the first disease-modifying therapy in development for #PMM2CDG, into a Phase 2b trial. @MedCityNews explains the unmet need, and why this work matters: medcitynews.com/2025/04/glycom… #CDGresearch

On #WorldCDGDay, we #StandUnited4CDG and remain focused on advancing GLM101, a potential disease-modifying therapy in #clinicaltrials for #PMM2CDG. Learn about the science behind GLM101: glycomine.com/glm101/ For more on #CDGawareness: worldcdg.org

Glycomine announced today the first participant dosed in POLAR, our global, randomized, placebo-controlled Phase 2b study of GLM101 for the treatment of #PMM2CDG, a rare genetic disorder of glycosylation. glycomine.com/glycomine-init… #CDGresearch #ClinicalTrial #RareDisease